Brief: Nexcella Announces 2023 Haematologica Editorial Highlighting Nxc-201 Efficacy In The Context Of U.S. FDA Approved Bcma Car T Cells

Immix Biopharma

31/03/2023 13:08

March 31 (Reuters) - Immix Biopharma Inc  IMMX.O :
    * NEXCELLA, AN IMMIX BIOPHARMA SUBSIDIARY, ANNOUNCES 2023
HAEMATOLOGICA EDITORIAL HIGHLIGHTING NXC-201 EFFICACY IN THE
CONTEXT OF U.S. FOOD AND DRUG ADMINISTRATION APPROVED BCMA CAR T
CELLS

Source text for Eikon:  ID:nGNX19hbw6 
Further company coverage:  IMMX.O 

 ((Reutersbriefs@thomsonreuters.com;))